Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalzanemdor - Sage Therapeutics

Next Previous
Drug Profile

Dalzanemdor - Sage Therapeutics

Alternative Names: SAGE-718

Latest Information Update: 23 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SAGE Therapeutics
  • Class Antidementias; Nootropics; Small molecules; Sterols
  • Mechanism of Action NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Huntington's disease
  • Phase II Dementia; Mild cognitive impairment
  • No development reported Cognition disorders
  • Discontinued Encephalitis; Smith-Lemli-Opitz syndrome

Most Recent Events

  • 17 Apr 2024 Efficacy and adverse events data from a phase II PRECEDENT trial in Parkinson’s Disease released by Sage Therapeutics
  • 09 Feb 2024 Sage Therapeutics completes a phase II trial in Mild cognitive impairment in USA (PO, Capsule) (NCT05318937)
  • 31 Jan 2024 Dalzanemdor receives 'Innovation Passport' designation under the Innovative Licensing and Access Pathway (ILAP) from the UK MHRA for cognitive impairment associated with Huntington’s disease
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top